Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Re

Vertex Pharmaceuticals (NASDAQ: VRTX - Get Free Report) and Molecular Partners (NASDAQ: MOLN - Get F

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the ana

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem

Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting

Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving preci

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partne

Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosi

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem

Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712Dosing ongoing

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIR

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. , May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcem

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partner

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.45) per share which missed the ana

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announceme

ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partner

MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast a

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  Ad hoc announcem

HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B

MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS

MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MS

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announce

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partn

Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partn

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partn

HC Wainwright & Co. analyst Robert Burns reiterates Molecular Partners (NASDAQ:MOLN) with a B

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.41) per share which missed the ana

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schliere

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partne

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical deve

HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOL

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, ini

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccel

Case study with first patient images of half-life engineered MP0712 from compassionate care use show

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate t

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.65) per share which missed the ana

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lo

In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with th